Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00425750 · OUTCOME

Progression-free Survival

Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer · Source last updated 2011-11-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Month
Interval / dispersion
95% Confidence Interval
Time frame
7.55 months (average duration, on study to off study)

What was measured

Median duration of survival without disease progression, calculated as on-study date to date of progression or date of death (censored) or off-study date (censored)

Groups in this outcome

Bortezomib; Docetaxel

Docetaxel will be given first at 40 mg/m2 IV on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1. Immediately afterwards, Bortezomib will be given at 1.6 mg/m2 IV on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bortezomib; Docetaxel25

Reported measurements

Source class 1
Values in Month · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bortezomib; Docetaxel2.27Not reported1.614.70Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.61
        upper Limit
        4.70
        value
        2.27
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
Median duration of survival without disease progression, calculated as on-study date to date of progression or date of death (censored) or off-study date (censored)
dispersion Type
95% Confidence Interval
groups
  1. description
    Docetaxel will be given first at 40 mg/m2 IV on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1. Immediately afterwards, Bortezomib will be given at 1.6 mg/m2 IV on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
    id
    OG000
    title
    Bortezomib; Docetaxel
param Type
MEDIAN
reporting Status
POSTED
time Frame
7.55 months (average duration, on study to off study)
title
Progression-free Survival
type
SECONDARY
unit Of Measure
Month

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice